Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Self-Reported Flourishing Among U.S. Surgeons: A National Physician Survey.

Journal of the American College of Surgeons·2026
Same author

American Journal of Transplantation at 25 years: A trusted voice.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Dual costimulation blockade with the CD154-specific fusion protein dazodalibep and belatacept for prophylaxis of kidney allograft rejection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

A Report of Four Depletional Induction Strategies in Non-Human Primate Islet Xenotransplantation.

Xenotransplantation·2026
Same author

Costimulatory blockade and infectious risk in solid organ transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Corrigendum to "Antibodies to angiotensin II type 1 receptor and endothelin type A receptor are associated with cytokine production enriched for type 2 immune response and antibody production in pediatric kidney transplant recipients" [American Journal of Transplantation. Volume 25, Issue 11, November 2025, Pages 2329-2344].

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2025

Related Experiment Video

Updated: Jul 8, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Alemtuzumab.

Timothy A Weaver1, Allan D Kirk

  • 1The Emory Transplantation Center, Emory University Hospital, Atlanta, GA, USA.

Transplantation
|January 1, 2008
PubMed
Summary
This summary is machine-generated.

Alemtuzumab, a CD52 antibody, shows promise as an induction agent in organ transplants, especially for minimizing long-term immunosuppression. This review covers its action and supporting evidence for transplantation protocols.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Experiment Videos

Last Updated: Jul 8, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pharmacology

Background:

  • Alemtuzumab is a CD52-specific monoclonal antibody.
  • It is increasingly used off-label in solid organ transplantation.
  • Its use aligns with maintenance immunosuppression minimization protocols.

Purpose of the Study:

  • To review the mechanism of action of alemtuzumab.
  • To summarize evidence supporting alemtuzumab's use as an induction agent.
  • To discuss its role in immunosuppression minimization in transplantation.

Main Methods:

  • Literature review of alemtuzumab's mechanism.
  • Synthesis of clinical evidence for its use in solid organ transplantation.
  • Analysis of its role in immunosuppression minimization strategies.

Main Results:

  • Alemtuzumab targets CD52-expressing lymphocytes, leading to their depletion.
  • Evidence supports its efficacy as an induction agent in various solid organ transplantations.
  • Its use facilitates reduced long-term immunosuppression, potentially lowering toxicity.

Conclusions:

  • Alemtuzumab is a valuable tool for induction therapy in solid organ transplantation.
  • It plays a key role in protocols aimed at minimizing maintenance immunosuppression.
  • Further research may solidify its standard use in specific transplant scenarios.